• Fri news: New Novo obesity prospect linked to psychiatric side effects. Summit beats Keytruda in NSCLC. DermaSensor skin cancer detection device. Astellas digital health product. Sanofi MS data. See more on our front page

Cue's IL-2-based Biologic Shows Early Promise in Head and Neck Cancer

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Nov 13, 2022 at 07:22: PM
via Early clinical data from a combination of Cue Biopharma's interleukin 2 (IL-2)-based biologic, CUE-101 and Merck's Keytruda shows the treatment is effective in patients with recurrent/metastatic HPV16+ head and neck cancer.

article source
 

<



Similar threads

cafead
Trials cue up new use for Roche&#039;s eye disease drug Vabysmo
Replies
0
Views
124
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Cue Health, Google&#039;s COVID-19 test provider, raises $200M in an IPO
Replies
0
Views
121
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Cue Biopharma downsizes to focus on autoimmune pipeline
Replies
0
Views
6
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Cue Health wins $28M BARDA contract to develop rapid respiratory infection test
Replies
0
Views
139
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Cue the M&amp;A chatter: UniQure is scouting for a buyout deal as gene therapy field...
Replies
0
Views
248
Pharma/Biotech Companies - In the News
cafead
cafead
Top Bottom
Back
Quote